News on Zelos Therapeutics Inc. from BioPortfolio.com http://www.BioPortfolio.com Consolidated Zelos Therapeutics Inc. news from BioPortfolio.com Tue, 09 Feb 2010 19:42:18 GMT en Zelos Therapeutics initiates dosing in Phase I osteoporosis trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994657&HITNO=0&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994657&THISHREF=http://c.moreover.com/click/here.pl%3fz2515184316%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3994657&HITNO=0&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3994657&THISHREF=http://c.moreover.com/click/here.pl%3fz2515184316%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Medical News: Zelos Therapeutics Initiates Dosing In A Phase 1 Clinical Study Of Nasal Spray Teriparatidehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988819&HITNO=1&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988819&THISHREF=http://c.moreover.com/click/here.pl%3fz2511537063%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3988819&HITNO=1&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3988819&THISHREF=http://c.moreover.com/click/here.pl%3fz2511537063%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatidehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983213&HITNO=2&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983213&THISHREF=http://c.moreover.com/click/here.pl%3fz2507712793%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3983213&HITNO=2&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3983213&THISHREF=http://c.moreover.com/click/here.pl%3fz2507712793%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Zelos Therapeutics commences dosing in clinical study of ZT-034 nasal spray for osteoporosishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980519&HITNO=3&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980519&THISHREF=http://c.moreover.com/click/here.pl%3fz2506439737%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3980519&HITNO=3&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3980519&THISHREF=http://c.moreover.com/click/here.pl%3fz2506439737%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatidehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981240&HITNO=4&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981240&THISHREF=http://c.moreover.com/click/here.pl%3fz2506874909%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3981240&HITNO=4&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3981240&THISHREF=http://c.moreover.com/click/here.pl%3fz2506874909%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatidehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3977429&HITNO=5&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3977429&THISHREF=http://c.moreover.com/click/here.pl%3fz2504811615%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3977429&HITNO=5&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3977429&THISHREF=http://c.moreover.com/click/here.pl%3fz2504811615%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatidehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976646&HITNO=6&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976646&THISHREF=http://c.moreover.com/click/here.pl%3fz2504445052%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976646&HITNO=6&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976646&THISHREF=http://c.moreover.com/click/here.pl%3fz2504445052%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study o...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976547&HITNO=7&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976547&THISHREF=http://c.moreover.com/click/here.pl%3fz2504418116%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976547&HITNO=7&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976547&THISHREF=http://c.moreover.com/click/here.pl%3fz2504418116%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comZibb: Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatidehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3977548&HITNO=8&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3977548&THISHREF=http://c.moreover.com/click/here.pl%3fz2504859588%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3977548&HITNO=8&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3977548&THISHREF=http://c.moreover.com/click/here.pl%3fz2504859588%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Joseph Zakrzewski, executive chairman, Amarinhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3898897&HITNO=9&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3898897&THISHREF=http://c.moreover.com/click/here.pl%3fz2463053789%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3898897&HITNO=9&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3898897&THISHREF=http://c.moreover.com/click/here.pl%3fz2463053789%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmafocus: Amarin Corporation Appoints Industry Veteran Joseph Zakrzewski as Executive Chairmanhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3724293&HITNO=10&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3724293&THISHREF=http://c.moreover.com/click/here.pl%3fz2374229436%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3724293&HITNO=10&MSIZE=11&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Zelos%20Therapeutics%20Inc.&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3724293&THISHREF=http://c.moreover.com/click/here.pl%3fz2374229436%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: